Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Enfermedad de Alzheimer y Demencias

134 ARTÍCULOS , VIENDO DEL 31 AL 45

Phenylbutyrate is a multifaceted drug that exerts neuroprotective effects and reverses the Alzheimer´s disease-like phenotype of a commonly used mouse model

Cuadrado-Tejedor M, Ricobaraza AL, Torrijo R, Franco R, Garcia-Osta A.

Curr Pharm Des. 2013;19(28):5076-84. doi: 10.2174/1381612811319280006.

[Posterior variant of Alzheimer's disease and other atypical symptom pictures]

Remes AM, Vanninen R, Jokinen H, Hallikainen M, Erkinjuntti T.

Duodecim. 2013;129(3):244-50.

Alzheimer's disease drug development: translational neuroscience strategies

Cummings JL, Banks SJ, Gary RK, Kinney JW, Lombardo JM, Walsh RR, Zhong K.

CNS Spectr. 2013 Jun;18(3):128-38. doi: 10.1017/S1092852913000023. Epub 2013 Mar 11.

Perspectives in molecular imaging using staging biomarkers and immunotherapies in Alzheimer's disease

Leclerc B, Abulrob A.

ScientificWorldJournal. 2013;2013:589308. doi: 10.1155/2013/589308. Epub 2013 Feb 5.

The role of cerebrospinal fluid biomarkers for Alzheimer's disease diagnosis. where are we now?

Papaliagkas VT.

Recent Pat CNS Drug Discov. 2013 Apr;8(1):70-8. doi: 10.2174/1574889811308010006.

Cerebrospinal fluid biomarkers for pathological processes in Alzheimer's disease

Rosén C, Zetterberg H.

Curr Opin Psychiatry. 2013 May;26(3):276-82. doi: 10.1097/YCO.0b013e32835f6747.

Clinical utility and analytical challenges in measurement of cerebrospinal fluid amyloid-β(1-42) and τ proteins as Alzheimer disease biomarkers

Kang JH, Korecka M, Toledo JB, Trojanowski JQ, Shaw LM.

Clin Chem. 2013 Jun;59(6):903-16. doi: 10.1373/clinchem.2013.202937. Epub 2013 Mar 21.

The AD-CSF-index discriminates Alzheimer's disease patients from healthy controls: a validation study

Molinuevo JL, Gispert JD, Dubois B, Heneka MT, Lleo A, Engelborghs S, Pujol J, de Souza LC, Alcolea D, Jessen F, Sarazin M, Lamari F, Balasa M, Antonell A, Rami L.

J Alzheimers Dis. 2013;36(1):67-77. doi: 10.3233/JAD-130203.

[Inflammatory markers in Alzheimer's disease and vascular dementia]

Androsova LV, Mikhaĭlova NM, Zozulia SA, Dupin AM, Rassadina GA, Lavrent'eva NV, Kliushnik TP.

Zh Nevrol Psikhiatr Im S S Korsakova. 2013;113(2):49-53.

Alzheimer's disease neurodegenerative biomarkers are associated with decreased cognitive function but not β-amyloid in cognitively normal older individuals

Wirth M, Madison CM, Rabinovici GD, Oh H, Landau SM, Jagust WJ.

J Neurosci. 2013 Mar 27;33(13):5553-63. doi: 10.1523/JNEUROSCI.4409-12.2013.

Comparing positron emission tomography imaging and cerebrospinal fluid measurements of β-amyloid

Landau SM, Lu M, Joshi AD, Pontecorvo M, Mintun MA, Trojanowski JQ, Shaw LM, Jagust WJ; Alzheimer's Disease Neuroimaging Initiative.

Ann Neurol. 2013 Dec;74(6):826-36. doi: 10.1002/ana.23908.

Machine learning and social network analysis applied to Alzheimer's disease biomarkers

Di Deco J, González AM, Díaz J, Mato V, García-Frank D, Álvarez-Linera J, Frank A, Hernández-Tamames JA.

Curr Top Med Chem. 2013;13(5):652-62. doi: 10.2174/1568026611313050008.

Effect of cognitive reserve markers on Alzheimer pathologic progression

Lo RY, Jagust WJ; Alzheimer’s Disease Neuroimaging Initiative.

Alzheimer Dis Assoc Disord. 2013 Oct-Dec;27(4):343-50. doi: 10.1097/WAD.0b013e3182900b2b.

Biomarkers of Alzheimer disease: current and future applications to diagnostic criteria

Sperling R, Johnson K.

Continuum (Minneap Minn). 2013 Apr;19(2 Dementia):325-38. doi: 10.1212/01.CON.0000429181.60095.99.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias